Vispa-cel (CB-010) for r/r LBCL - Vispa-cel demonstrated an 86% Overall Response Rate (ORR) in the optimized profile group [30, 84] - Vispa-cel achieved a 63% Complete Response (CR) rate in the optimized profile group [30, 84] - Vispa-cel showed a 53% 12-month Progression-Free Survival (PFS) rate in the optimized profile group [30, 84] - Caribou Biosciences anticipates initiating a pivotal phase 3 clinical trial for Vispa-cel in 2L LBCL CD19-naïve patients [3] CB-011 for r/r MM - CB-011 achieved a 92% Overall Response Rate (ORR) in BCMA-naïve patients at the recommended dose for expansion (RDE) [91] - CB-011 demonstrated a 75% ≥ Complete Response (CR) rate in BCMA-naïve patients at the RDE [91] - CB-011 showed a 91% Minimal Residual Disease (MRD) negativity rate in evaluable BCMA-naïve patients at the RDE [91] - 7 out of 12 patients achieved ≥VGPR (Very Good Partial Response) at ≥6 months with CB-011 at the RDE [91] Financial Position - Caribou Biosciences expects to report approximately $159.2 million in cash, cash equivalents, and marketable securities as of September 30, 2025 [3, 137, 138] Manufacturing - Vispa-cel manufacturing has the potential for 96% lower COGS (Cost of Goods Sold) than current autologous CAR-T cell therapies [15, 80]